近年来，肺癌的发病率逐年上升，已成为我国发病率和死亡率均位居首位的癌症。近些年来，中国的肺癌研究也取了的了长足的进展，在国际舞台上崭露头角。2018年11月7日，IASLC与中国专家再度合作，与中国抗癌协会肺癌专业委员会、中国胸部肿瘤研究协作组联合主办2018年亚洲肺癌大会（ACLC 2018），来自全世界肺癌研究领域的大咖就肺癌领域的最新研究进行了精彩的演讲和讨论，为听众带来了一场学术盛宴。本次大会上，共评选出14个获奖摘要（Best Abstract），中国研究表现抢眼。
2018亚洲肺癌大会（Asia Conference on Lung Cancer, ACLC 2018）在经过国际评审专家的独立评审、打分，综合全部专家的最后评分后评选出来14个获奖摘要。多数研究都集中在肺癌的精准治疗领域，多项中国研究入选，表现抢眼。
LKB1 pathway variant TSC2 rs30259 predicts the prognosis in early stage non-small cell lung cancer
LKB1通路TSC2 rs30259变异预测早期非小细胞肺癌预后
大会发言：Eungbase Lee
Targeted Next-Generation Sequencing Reveals Relapse-Associated Genomic Alterations in Early Stage Non-Small Cell Lung Cancer
二代测序揭示早期非小细胞肺癌复发相关基因突变
大会发言： William C. Cho
阿法替尼序贯奥希替尼在晚期EGFR突变非小细胞肺癌的真实世界研究（Giotag）
大会发言：杨志新
研究团队：Maximilian J. Hochmair,Alessandro Morabito,Desiree Hao,Cheng-Ta Yang,Ross A. Soo,James C-H Yang,RasimGucalp,BalazsHalmos,Lara Wang,Amanda Golembesky,Angela Märten,Tanja Cufer
Factors Influencing the Non-Administration of Chemotherapies in Patients Who Progressed After First-Line EGFR-TKIs
一线EGFR-TKI耐药后不接受化疗相关因素分析
大会发言：Takaaki Mizuno
研究团队：Takaaki Mizuno, Hidehito Horinouchi, Sho Watanabe, Jun Sato, Ryo Morita,Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda, Yutaka Fujiwara, Noboru Yamamoto, Yuichiro Ohe;
Tumor Mutational Burden Standardization Initiative: Establish a Consistent Methodology for TMB Measurement in Clinical Samples
肿瘤突变负荷标准化倡议：构建临床样本TMB计算标准方法学
大会发言：Virginia Ip
研究团队：Albrecht Stenzinger, Jeff Allen, Jörg Maas, Mark Stewart, Diana Merino,Manfred Dietel, Virginia Ip;
Tepotinib in Non-Small Cell Lung Cancer with MET Exon 14-Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress
Tepotinib在MET 14跳跃或扩增非小细胞肺癌的II期临床研究
大会发言：Paul Paik
研究团队：Paul Paik, Hiroshi Sakai, Rolf Bruns, Jürgen Scheele, Josef Straub, Enriqueta Felip;
Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
中国肺癌人群ERBB2 20外显子插入突变临床特征及阿法替尼治疗临床转归分析
大会发言：刘哲峰
研究团队：Zhefeng Liu, Yi Hu, Lin Wu, Jun Cao, Zhe Yang, Chengzhi Zhou, Liming Cao, Hao Wu, Haibo Shen, Meiling Jin, Yong Zhang, Jianxing Xiang, Ke Ma, Bing Li, Tengfei Zhang, Xinru Mao;
Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-Small Cell Lung Cancer
Sintilimab联合一线化疗在晚期肺鳞癌疗效及安全性探索
大会发言：应可净
研究团队：Kejing YING., Nong XU, Haiping JIANG, Yunpeng LIU, Hui ZHOU, Shuyan WANG.
High-dose icotinib in advanced NSCLC with EGFR 21 L858R mutation: a randomized, open-label phase II study
高剂量埃克替尼在晚期L858R突变非小细胞肺癌开放标签随机对照II期研究
大会发言：李曦
研究团队：Xi Li, Li Zhang, Da Jiang, Yan Wang, Aimin Zang, Cuimin Ding, Min Zhao, Wuyun Su, Yan Zhang, Diansheng Zhong, Jin Wu, Guangyu An, Cuiying Zhang, Xingsheng Hu, Gang Cheng, Huaqing Wang, Zhihai Han, Xiaohui He, Junli Liu, Li Liang, Shucai Zhang;
Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Tepotinib联合吉非替尼在MET阳性/EGFR突变非小细胞肺癌II期研究
大会发言：程颖
研究团队：Ying Cheng, Jianying Zhou, Shun Lu3, Yiping Zhang, Jun Zhao, Hongming Pan, Yuh-Min Chen, Chih-Feng Chian, Rolf Bruns, Andreas Johne, Jürgen Scheele, Yi-Long Wu;
Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Repotrectinib在晚期ROS1融合突变非小细胞肺癌初步临床疗效
大会发言：Ignatius Ou
研究团队：Sai-Hong I. Ou, ByoungChulCho, Dong-Wan Kim, Alexander Drilon, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung-Ju Ahn, D. Ross Camidge, Shanna Stopatschinskaja, Juliet Liu, Jean Cui, David M. Hyman, Robert C. Doebele, Alice T. Shaw
CheckMate 078: Patient-Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non-Small Cell Lung Cancer (NSCLC)
Nivolumab对比多西他赛在晚期非小细胞肺癌（Checkmate078）的患者报告临床转归
大会发言：吴一龙
研究团队：Yi-Long Wu, MD;JianhuaChang, MD, PhD;Li Zhang, MD;Hai-Yan Tu, MD;Lin Wu, MD;Jifeng Feng, MD;Shun Lu, MD, PhD;Caicun Zhou, MD, PhD;Jie Wang, MD;Tony Mok, MD;Fiona Taylor, MBiochem;Brenna Mossman, MA;John R. Penrod, PhD;Rachael Lawrance;Steven I. Blum, MBA, MA;Peter F. Wang, MD, PhD;Ying Cheng, MD
First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (≥10 mut/Mb): Results From CheckMate 227
一线Nivolumab联合Ipilimumab在亚洲晚期合并高肿瘤突变负荷非小细胞肺癌研究结果
大会发言： Keunchil Park
研究团队：Keunchil Park, Jong S. Lee, Hiroshi Sakai, Ki H. Lee, Yuichiro Ohe, Sang-We，Kim, Tatsuro Fukuhara, Jin-Hyoung Kang, Chong-Jen Yu, Haruko Daga,Katsuyuki Hotta, Toshihide Yokoyama, Hiroshi Tanaka, Masayuki Takeda, Matthew D. Hellmann, Jennifer Sheng, Faith Nathan, Rong Yang, Makoto Nishio;
A Phase I Study of Novel Bcl-2/Bcl-xL Inhibitor APG-1252 in Patients with Advanced SCLC or Other Solid Tumor
Bcl2/Bcl-xL抑制剂APG-1252在晚期小细胞肺癌或其它实体瘤中I期研究
大会发言：周清
研究团队：Yi-long Wu, Nehal J Lakhani, Michael Boyer, Qing Zhou, Drew W Rasco, Yingjie Huang, Lichuang Men, Yufeng Li, Zhenzhong Xia, Hengbang Wang, Jiao Ji, Baoer Lu, Zicong He, Qi Dong, Dajun Yang, Yifan Zhai;
苏公网安备32059002004080号
